On Thursday, Shares of Apple Inc. (NASDAQ:AAPL), gained 1.33% to $128.51.
Worldpay, a leading global provider of payment and risk services, will offer its customers access to Apple Pay, a new category of service that transforms mobile payments with an easy, secure and private way to pay when it launches in the UK next month.
As the UK’s leading payment provider, Worldpay is known for bringing innovative new technology to retailers and assisting them to offer a better shopping experience. Having accepted the first contactless payment ever made in the UK, Worldpay has been instrumental in the adoption of Near Field Communication (NFC) technology, processing £2billion worth of contactless payments in just four years*.
In readiness for the launch of Apple Pay, Worldpay is working with retailers of all sizes across the UK to make over 250,000 card machines capable of accepting NFC payments. With Worldpay’s support, well-known high street brands like Arcadia , Dune, SPAR, and others who accept contactless cards at the Point of Sale, will also soon be able to accept Apple Pay.
To support the rapid growth of m-commerce and in-app purchases in the UK, Worldpay is also assisting to integrate Apple Pay into some of the world’s biggest travel and retail apps. Worldpay customers will be able to accept Apple Pay in iOS apps to improve their online conversion - all without needing to develop a bespoke payment capability.
Apple Inc. designs, manufactures, and markets mobile communication and media devices, personal computers, watches, and portable digital music players worldwide. The company also sells related software, services, accessories, networking solutions, and third-party digital content and applications.
Shares of Fitbit Inc. (NYSE:FIT), inclined 1.04% to $47.78, during its last trading session.
As the popularity of organized runs continues to grow, Fitbit, Inc., the leader in the connected health and fitness market, is increasing its efforts to assist consumers reach their fitness aims through new partnerships with The San Francisco Marathon and Destination Races. With industry-leading devices, impactful data and virtual coaching, Fitbit assists users prepare for and reach their performance aims at any level, from concluding a first 5K run to setting a personal record for a half or full marathon.
“By supporting events like The San Francisco Marathon and Destination Races, Fitbit is assisting provide positive experiences for runners of all levels to train and reach their aims,” said Tim Rosa, VP Global Marketing, Fitbit. “We want to enable people to train smarter by providing them with the tools to take their training to a new level, such as logging workouts and monitoring heart rate. We’re excited to see runners of all levels go farther and faster this race season with the assist of Fitbit.”
Fitbit Inc. provides wearable fitness-tracking devices worldwide. The company makes both wrist bands and clippable devices that monitor a user’s fitness activity by tracking the calories burned or distance covered.
Finally, Chiasma, Inc (NASDAQ:CHMA), ended its last trade with 25% surge, and closed at $20, hitting its highest level.
Chiasma, declared the pricing of its initial public offering of 6,365,000 shares of common stock at a price of $16.00 per share, before underwriting discounts. All of the common stock is being offered by Chiasma. In addition, Chiasma has granted the underwriters a 30-day option to purchase up to 954,750 additional shares of common stock at the public offering price, before underwriting discounts.
Barclays Capital Inc. and Cowen and Company, LLC acted as joint book-running managers for the offering. William Blair & Company, L.L.C. and Oppenheimer & Co. Inc. acted as co-managers.
Chiasma, Inc. (Chiasma) is a biopharmaceutical company. The Company is focused on improving the lives of patients suffering from orphan diseases by developing and commercializing oral forms of therapies that are accessible by injection. Using the Company’s Transient Permeability Enhancer (TPE), technology platform, it develops oral therapies associated with existing injectable therapies.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
